Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

824 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.
Dietz-Fricke C, Tacke F, Zöllner C, Demir M, Schmidt HH, Schramm C, Willuweit K, Lange CM, Weber S, Denk G, Berg CP, Grottenthaler JM, Merle U, Olkus A, Zeuzem S, Sprinzl K, Berg T, van Bömmel F, Wiegand J, Herta T, Seufferlein T, Zizer E, Dikopoulos N, Thimme R, Neumann-Haefelin C, Galle PR, Sprinzl M, Lohse AW, Schulze Zur Wiesch J, Kempski J, Geier A, Reiter FP, Schlevogt B, Gödiker J, Hofmann WP, Buggisch P, Kahlhöfer J, Port K, Maasoumy B, Cornberg M, Wedemeyer H, Deterding K. Dietz-Fricke C, et al. Among authors: galle pr. JHEP Rep. 2023 Mar 15;5(4):100686. doi: 10.1016/j.jhepr.2023.100686. eCollection 2023 Apr. JHEP Rep. 2023. PMID: 37025462 Free PMC article.
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.
Sangro B, Galle PR, Kelley RK, Charoentum C, De Toni EN, Ostapenko Y, Heo J, Cheng AL, Wilson Woods A, Gupta C, Abraham J, McCoy CL, Patel N, Negro A, Vogel A, Abou-Alfa GK. Sangro B, et al. Among authors: galle pr. J Clin Oncol. 2024 May 28:JCO2301462. doi: 10.1200/JCO.23.01462. Online ahead of print. J Clin Oncol. 2024. PMID: 38805668
PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Abou-Alfa GK, Galle PR, Chao Y, Erinjeri J, Heo J, Borad MJ, Luca A, Burke J, Pelusio A, Agathon D, Lusky M, Breitbach C, Qin S, Gane E. Abou-Alfa GK, et al. Among authors: galle pr. Liver Cancer. 2023 Sep 30;13(3):248-264. doi: 10.1159/000533650. eCollection 2024 Jun. Liver Cancer. 2023. PMID: 38756145 Free PMC article.
Evidence and Choice: The BCLC Vision for Tailoring Clinical Decision-Making.
Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. Reig M, et al. Among authors: galle pr. J Hepatol. 2024 May 8:S0168-8278(24)00321-0. doi: 10.1016/j.jhep.2024.04.023. Online ahead of print. J Hepatol. 2024. PMID: 38729354 No abstract available.
PHES scores have limited impact on the risk of overt HE in patients with minimal HE.
Gairing SJ, Mangini C, Zarantonello L, Jonasson E, Danneberg S, Sultanik P, Galle PR, Gioia S, Labenz J, Lok AS, Marquardt JU, Lauridsen MM, Bloom PP, Thabut D, Nardelli S, Montagnese S, Labenz C. Gairing SJ, et al. Among authors: galle pr. Hepatol Commun. 2024 May 3;8(5):e0438. doi: 10.1097/HC9.0000000000000438. eCollection 2024 May 1. Hepatol Commun. 2024. PMID: 38701395 Free PMC article.
Lower uromodulin serum levels are associated with poorer prognosis in patients with cirrhosis and hepatorenal syndrome type 2.
Schleicher EM, Gairing SJ, Castven D, Hock CS, Dobbermann H, Heinrich S, Meineck M, Kaps L, Galle PR, Weinmann-Menke J, Nguyen-Tat M, Marquardt JU, Labenz C. Schleicher EM, et al. Among authors: galle pr. Am J Physiol Gastrointest Liver Physiol. 2024 May 1;326(5):G583-G590. doi: 10.1152/ajpgi.00304.2023. Epub 2024 Mar 19. Am J Physiol Gastrointest Liver Physiol. 2024. PMID: 38502914
Short-term reduction of dietary gluten improves metabolic-dysfunction associated steatotic liver disease: A randomised, controlled proof-of-concept study.
Armandi A, Bespaljko H, Mang A, Huber Y, Michel M, Labenz C, Galle PR, Neerukonda M, Bugianesi E, Schuppan D, Schattenberg JM. Armandi A, et al. Among authors: galle pr. Aliment Pharmacol Ther. 2024 May;59(10):1212-1222. doi: 10.1111/apt.17941. Epub 2024 Mar 11. Aliment Pharmacol Ther. 2024. PMID: 38462919 Clinical Trial.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Among authors: galle pr. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
AIDS-defining events among people living with HIV who have been under continuous antiretroviral therapy for more than one year, a German cohort study 1999-2018.
Pantke A, Kollan C, Gunsenheimer-Bartmeyer B, Jensen BO, Stephan C, Degen O, Schürmann D, Kurth T, Bremer V, Koppe U; HIV-1 Seroconverter Cohort and the ClinSurv HIV Cohort. Pantke A, et al. Infection. 2024 Apr;52(2):637-648. doi: 10.1007/s15010-024-02188-y. Epub 2024 Feb 21. Infection. 2024. PMID: 38381307 Free PMC article.
824 results